What Is MTHFR Variant

An MTHFR variant is a genetic polymorphism in the gene encoding the enzyme methylenetetrahydrofolate reductase, which converts folate into its biologically active form, 5-methyltetrahydrofolate (5-MTHF). The two most studied variants, C677T and A1298C, reduce the enzyme's catalytic efficiency to varying degrees. Because the active form of folate is required for methylation, a core biochemical process that touches DNA repair, neurotransmitter balance, and detoxification, reduced MTHFR function can have ripple effects across multiple systems.

Methylation is one of the most frequent biochemical reactions in the body, occurring billions of times per second. It governs the addition of methyl groups to DNA, proteins, and small molecules, influencing gene expression, synthesis of creatine and phosphatidylcholine, recycling of homocysteine back to methionine, and the production of glutathione (the body's primary intracellular antioxidant). When MTHFR enzyme activity is reduced, the supply of 5-MTHF shrinks, and the methylation cycle can slow. The most measurable downstream effect is a rise in homocysteine, an amino acid intermediate that, when elevated, is epidemiologically linked to cardiovascular disease, cognitive decline, and pregnancy complications.

For longevity, MTHFR status matters because it sits upstream of processes central to aging: DNA methylation patterns shift with age and are used in epigenetic clocks to estimate biological age; glutathione capacity influences oxidative stress resilience; and homocysteine itself appears to accelerate vascular and neurological aging. Understanding one's MTHFR genotype does not reveal a destiny, but it does highlight a metabolic leverage point where relatively simple nutritional adjustments (choosing the right form of folate, ensuring adequate B12 and B6) can support an enzymatic bottleneck that would otherwise quietly erode methylation capacity over decades.

The MTHFR enzyme catalyzes the irreversible conversion of 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate (5-MTHF). This product is the principal methyl donor for the remethylation of homocysteine to methionine, a reaction carried out by the enzyme methionine synthase with vitamin B12 as a cofactor. Methionine is then converted into S-adenosylmethionine (SAMe), the universal methyl donor used in over 200 enzymatic reactions throughout the body. When MTHFR activity is diminished, less 5-MTHF is produced, SAMe generation slows, and homocysteine accumulates.

The C677T variant involves a single nucleotide change (cytosine to thymine at position 677) that substitutes alanine with valine in the enzyme protein. This substitution makes the enzyme thermolabile, meaning it loses activity more readily at body temperature. One copy of the variant (heterozygous) reduces enzyme activity by approximately 30 to 35 percent; two copies (homozygous) reduce it by approximately 60 to 70 percent. The A1298C variant (adenine to cytosine at position 1298) produces a smaller reduction in enzyme activity and affects a different functional domain of the protein. Compound heterozygosity (one copy of C677T and one copy of A1298C) can produce functional effects that fall between the two single-variant states.

Because the methylation cycle connects to glutathione synthesis (through the transsulfuration pathway), to DNA methylation, and to the production of neurotransmitters such as serotonin, dopamine, and norepinephrine, reduced MTHFR activity can present in diverse ways. Some carriers experience elevated homocysteine with no symptoms; others report fatigue, mood instability, or chemical sensitivities. The phenotypic outcome depends heavily on dietary folate and B-vitamin intake, gut absorption capacity, and other genetic variants affecting the same pathways (such as COMT, MTR, and MTRR).

The association between MTHFR C677T homozygosity and elevated homocysteine is well established across large population studies and meta-analyses. Elevated homocysteine, in turn, has been consistently linked to increased risk of cardiovascular disease, stroke, and venous thromboembolism in observational data. The relationship between MTHFR variants and neural tube defects during pregnancy is one of the best-replicated findings in genetic epidemiology, and it informed global folic acid fortification policies. Some research connects MTHFR variants to increased rates of depression, cognitive decline, and certain cancers, but these associations are generally modest and influenced by numerous confounding variables.

The evidence for supplementation is more nuanced. Trials using folic acid and B vitamins to lower homocysteine have shown reliable reductions in homocysteine levels but mixed results for reducing cardiovascular events in general populations. However, these trials typically used folic acid rather than methylfolate, and most did not stratify by MTHFR genotype, making it difficult to draw genotype-specific conclusions. Observational and smaller clinical studies suggest that methylfolate may be more effective than folic acid for MTHFR carriers, particularly for improving folate status and lowering homocysteine. Research on MTHFR and mental health, detoxification capacity, and epigenetic aging is ongoing but still early in establishing causation rather than association.

MTHFR variants are common genetic polymorphisms, not rare mutations, and many carriers live without any identifiable health consequence. Overmethylation from excessive methylfolate supplementation can cause anxiety, irritability, insomnia, and headaches, particularly in individuals with certain COMT genotypes or those who are already well-methylated. Starting with low doses and titrating up is sensible. Some practitioners and direct-to-consumer testing companies overstate the clinical significance of MTHFR status, attributing a wide range of symptoms to a single gene variant without adequate context; genotype should always be interpreted alongside functional markers such as homocysteine levels and clinical presentation.